← board
ACOG
distress 4/10 · elevated risk$8.28+5%today-23% from 52w high
Revenue
pre-revenue
Liquidity
$54M
Runway
1.8 yrs
Shares 1y
+35%
Price & events
+45.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.8%
1D
-0.9%
1W
+25.9%
1M
+20.9%
3M
+39.1%
6M
-17.1%
1Y
—
2Y
—
5Y
+45.2%
All
Overview
- Market Cap
- $180.25M
- Volume
- 3.71K
- 52 Week Range
- $4.50 – $10.81
- Total Shares
- 21.77M
- Float Shares
- 11.42M
- Short %
- 0.75%
- % Held by Insiders
- 5.28%
- % Held by Institutions
- 54.13%
- RVOL
- 0.06x
- Beta
- 2.33
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (1)
- ZUNVEYLBENZGALANTAMINE GLUCONATE2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+93% upside) · 4 analysts
- 2026-07-10Raymond JamesOutperform
- 2026-05-29Maxim GroupBuy
- 2026-05-22HC Wainwright & Co.Buy
- 2026-04-27HC Wainwright & Co.Buy
- 2026-04-17Craig-HallumBuy
- 2025-12-19HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-22ACOG Options Chain — NASDAQ:ACOG - TradingView
- 2026-07-21ACOG Issues Updated Guidance on HIV Screening and Prevention, Stronger Recommendations for PrEP - POZ
- 2026-07-20ACOG Releases New Guidance on HIV Screening and Prevention - Patient Care Online
- 2026-07-20Alpha Cognition’s RESOLVE Study: Fresh Real‑World Data on Zunveyl in Alzheimer’s Care - TipRanks
- 2026-07-18ACOG Clinical Consensus No. 10: Cannabis Use... : Obstetrics & Gynecology - Lippincott Home
- 2026-07-17No Clear Evidence Of Link Between Tylenol And Autism, ACOG Says Arisa Dimagrita (OkzvuXyHlE) - Mshale
- 2026-07-17ACOG updates guidance on HIV screening and prevention - Healio
- 2026-07-17ACOG Updates Guidelines on Postmenopausal Bleeding Evaluation - Endocrinology Advisor
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.